Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J, Liu H, Shen HL, Yue LZ, Yang XJ, Song WJ, Sun CY, Yu SZ, Ding K, Wang YH, Li LJ, Yu H, Shao YY, Wang CM, Yue SY, Fu R. Song J, et al. Among authors: shao yy. Zhonghua Xue Ye Xue Za Zhi. 2021 Nov 14;42(11):917-922. doi: 10.3760/cma.j.issn.0253-2727.2021.11.006. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 35045653 Free PMC article. Chinese.
Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet.
Hsieh YY, Su YL, Kuan FC, Chen SG, Chang CL, Shao YY, Tsai CW, Liang YH. Hsieh YY, et al. Among authors: shao yy. Am J Cancer Res. 2024 Dec 15;14(12):5909-5920. doi: 10.62347/MUCQ4129. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803663 Free PMC article.
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.
Kudo M, Tsuchiya K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M. Kudo M, et al. Among authors: shao yy. Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. eCollection 2024 Aug. Liver Cancer. 2023. PMID: 39114762 Free PMC article.
196 results